Table 5 Lipid-based drug-loaded Nano-DDS of Passive CL targeting
From: Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight
Nanosystem engineered | Loaded anti-leishmanial drug | Core components for fabrication | Characterization | Animal model | Major results | References |
|---|---|---|---|---|---|---|
Liposomes | Meglumine Antimonate | Sphingosylphosphorylcoline Cholesterol Propylene glycol | In vitro + In vivo | L. major infected BALB/c mice | Designed nano-formulation was associated with significantly lower lesion size and splenic parasites post-treatment | [181] |
Amphotericin-B | Phosphatidylcholine Cholesterol | In vitro + In vivo | L. tropica infected BALB/c mice | Topical L-Amp-B 0.4% was found with the capability to complete eradication of skin lesions and splenic parasites as well | [182] | |
Miltefosine | Phosphatidylcholine Cholesterol Propylene glycol | In vitro + In vivo | L. major infected BALB/c mice | Lesion size and parasitic burden reduction with 2% and 4% MFS loaded LPS | [183] | |
Transfersomes | Sodium Stibogluconate | Phospholipon G Tween 80 | In vitro + In vivo | L. tropica infected BALB/c mice | Drug loaded TFS shown to have tenfold improved deep epidermal permeation and fourfold lower IC50 as compared to the plain drug solution | [163] |
Rifampicin | Phospholipon G Span 60 & 80 Tween 20 & 80 Sodium lauryl sulfate | In vitro + In vivo | L. tropica infected BALB/c mice | Lower IC50 (for leishmanial cellular apoptosis) of rifampicin loaded TFS was observed | [177] | |
Nano-structured lipid Carriers | Amphotericin-B | Phospholipon G Isopropyl myristate Glyceryl monosterate | In vitro + In vivo | L. major infected BALB/c mice | Significant parasitic burden reduction in leishmanial lesion | [185] |